Elizabeth Averill
Family · Candler, NCNPI 1033545926
Payments from drug & device makers
Across 61 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$209
- GSK$125
- Exact Sciences$103
- Novo Nordisk$93
- AbbVie$79
- Corcept Therapeutics$69
- plus $431 from 16 others
What the payments were for
- Food & beverage$1,108100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $209 |
| GSK | 6 | $125 |
| Exact Sciences | 6 | $103 |
| Novo Nordisk | 6 | $93 |
| AbbVie | 4 | $79 |
| Corcept Therapeutics | 4 | $69 |
| Amgen | 3 | $55 |
| AstraZeneca | 3 | $49 |
| Inari Medical, Inc. | 2 | $43 |
| Radius Health, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Stryker | 1 | $20 |
| Seqirus USA Inc | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Medtronic | 1 | $18 |
| Abbott | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$1,108 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $73,117 |
| EliquisApixaban | 82 | $68,055 |
| XareltoRivaroxaban | 46 | $49,974 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $30,689 |
| OzempicSemaglutide | 19 | $27,161 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $16,697 |
| FarxigaDapagliflozin Propanediol | 27 | $15,474 |
| JanuviaSitagliptin Phosphate | 17 | $13,563 |
| Repatha SureclickEvolocumab | 16 | $12,097 |
| TradjentaLinagliptin | 12 | $11,136 |
| MyrbetriqMirabegron | 15 | $8,286 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $7,541 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $7,158 |
| LinzessLinaclotide | 11 | $6,096 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 17 | $5,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $16 | $84,25268 claims |
| PfizerEliquis, Paxlovid | $209 | $69,484103 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy, Shingrix | $125 | $63,25498 claims |
| Novo NordiskOzempic | $93 | $27,16119 claims |
| AstraZenecaFarxiga | $49 | $15,47427 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $8,28615 claims |
| AbbVieLinzess, Synthroid | $79 | $8,01133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.
Other family in Candler
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.